Detalhe da pesquisa
1.
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma.
Blood
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713888
2.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(2): 139-150, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36642080
3.
Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
Chemotherapy
; 67(4): 201-210, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35249035
4.
Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma.
Eur J Haematol
; 104(1): 59-66, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31606909
5.
Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group.
Adv Clin Exp Med
; 32(1): 131-136, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36603138
6.
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, dexamethasone or lenalidomide alone.
Pol Arch Intern Med
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38747414
7.
Safe administration of rituximab in patients with chronic lymphocytic leukemia and a history of obinutuzumabassociated anaphylaxis.
Pol Arch Intern Med
; 128(7-8): 494-495, 2018 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-30174325